Safety and efficacy of dual tyrosine kinase 2 inhibitor and monoclonal antibody therapy for psoriasis and psoriatic arthritis

Br J Dermatol. 2024 Feb 16;190(3):451-453. doi: 10.1093/bjd/ljad473.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Arthritis, Psoriatic* / drug therapy
  • Humans
  • Immunotherapy
  • Psoriasis* / drug therapy
  • TYK2 Kinase
  • Treatment Outcome

Substances

  • TYK2 Kinase
  • Antibodies, Monoclonal